

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	47	EP	526 511	B1		05-28-1997		<input type="checkbox"/>
	92	GB	2 220 211	A		01-04-1990		<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance, and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3154027 v2

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenck
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	207	5,780,587		Potter	07-14-1998	
	197	5,744,368		Goldhaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	175	5,441,870		Seubert, et al.	08-15-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	32	5,187,153		Cordell et al.	02-16-93	
	198	5,004,697		Pardridge	04-0201991	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Office ⁴	Number ⁴	Kind Code ⁵ (if known)				
	187	EP	783 104	A1		07-09-1997		<input type="checkbox"/>
	199	PCT	00/77178	A1		12-21-2000		<input type="checkbox"/>
	188	PCT	00/43049	A1		07-27-2000		<input type="checkbox"/>
	58	PCT	99/27944	A1		06-10-1999		<input type="checkbox"/>
	203	PCT	99/00150	A2		01-07-1999		<input type="checkbox"/>
	202	PCT	97/21728	A1		06-19-1997		<input type="checkbox"/>
	208	PCT	96/28471	A1		09-19-1996		<input type="checkbox"/>
	200	PCT	95/12815	A1		05-11-1995		<input type="checkbox"/>
	201	PCT	94/28412	A1		12-08-1994		<input type="checkbox"/>
	205	PCT	93/04194	A1		03-04-1993		<input type="checkbox"/>
	87	PCT	89/01343	A1		02-23-1989		<input type="checkbox"/>

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEE OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3158407 v3

FORM PTO-1449 (Modified)			Attorney Docket No.: 15270-004740US		Application No.: 09/322,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Dale B. Schenk		Filing Date: May 28, 1999	
					Group: 1648	
BA 75	WO 93/15760	8/19/93	PCT			
BA 76	WO 93/14200	7/22/93	PCT			
BA 77	WO 93/02189	2/4/93	PCT			
BK 79	WO 92/06708	4/30/92	PCT			
BL 80	WO 92/06187	4/16/92	PCT			
BM 81	WO 91/19810	12/26/91	PCT			
BM 82	WO 91/16819	11/14/91	PCT			
BO 83	WO 91/12816	9/5/91	PCT			
BE 84	WO 91/08760	6/27/91	PCT			
BO 85	WO 90/12871	11/1/90	PCT			
BK 86	WO 90/12870	11/1/90	PCT			
BE 88	WO 89/06242	7/13/89	PCT			
BT 89	WO 89/06689	7/27/89	PCT			
BO 91	WO 88/10120	12/29/88	PCT			
BE 48	EP 506 785	3/15/00	Europe			
BE 43	EP 639 081	11/3/99	Europe			
BE 46	EP 561 087	8/4/99	Europe			
BE 35	EP 911 036	4/28/99	Europe			
BE 42	EP 652 962	12/16/98	Europe			
CA 37	EP 863 211	9/9/98	Europe			
CB 38	EP 845 270	6/3/98	Europe			
CE 45	EP 594 607	8/27/97	Europe			
CE 39	EP 782 859	7/9/97	Europe			
CE 50	EP 440 619	1/24/96	Europe			
CE 51	EP 359 783	11/29/95	Europe			
CA 40	EP 683 234	11/22/95	Europe			
CA 41	EP 666 080	8/9/95	Europe			
CA 49	EP 451 700	10/16/91	Europe			
CA 93	GB 2 335 192	9/15/99	United Kingdom			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
CA 94	Andersen et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?," <i>Neurology</i> , 45:1441-1445 (1995).					
CA 95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <i>The Boston Globe</i> (4/13/95).					
CA 96	Bauer et al., "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <i>FEBS Letters</i> , 285(1):111-114 (1991).					
CA 98	Bodmer et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <i>Biochem. Biophys. Res. Comm.</i> , 171(2):890-897 (1990).					
CA 97	Blass, John P., "Immunologic Treatment of Alzheimer's Disease," <i>New England J. Medicine</i> , 341(22):1694 (1999).					

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk	
		Filing Date: May 28, 1999	Group: 1648
— CR 101	Brice et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," <i>J. Neurology, Neurosurg. Psychiatry</i> , 56:112-115 (1993).		
— CR 102	Chao et al., "Transforming Growth Factor- β Protects human Neurons Against β -Amyloid-Induced Injury," <i>Soc. Neurosci. Abstracts</i> , 19:513.7 (1993).		
— CR 105	Felsenstein et al., "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <i>Neuroscience Letters</i> , 152:185-189 (1993).		
— CR 106	Finch et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <i>Neurobiology of Aging</i> , 17(5):809-815 (1996).		
— CR 107	Fisher et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <i>PNAS</i> , 88:1779-1782 (1991).		
— CR 108	Flanders et al., "Altered expression of transforming growth factor- β in Alzheimer's disease," <i>Neurology</i> , 45:1561-1569 (1995).		
— CR 110	Gandy et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <i>TIPS</i> , 13:108-113 (1992).		
— CR 115	Goate et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <i>Nature</i> , 349:704-706 (1991).		
— CR 116	Gozes et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <i>PNAS</i> , 93:427-432 (1996).		
— CR 118	Haga et al., "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <i>Brain Research</i> , 601:88-94 (1993).		
— CR 121	Hardy, John, "New Insights into the Genetics of Alzheimer's Disease," <i>Annals of Med.</i> , 28:255-258 (1996).		
— DA 123	Huberman et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <i>J. Neuroimmunology</i> , 52:147-152 (1994).		
— DB 124	Hyman et al., "Molecular Epidemiology of Alzheimer's Disease," <i>N. E. J. Medicine</i> , 333(19):1283-1284 (1995).		
— DE 125	Itagaki et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <i>J. Neuroimmunology</i> , 24:173-182 (1989).		
— DP 127	Kalaria, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <i>Res. Immunology</i> , 143:637-641 (1992).		
— DE 128	Kawabata et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <i>Nature</i> , 354:476-478 (1991).		
— DF 129	Lampert-Etchells et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <i>Neurodegeneration</i> , 2:111-121 (1993).		
— DE 131	Lannfelt et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <i>Behavioural Brain Res.</i> , 57:207-213 (1993).		
— DF 136	Meda et al., "Activation of microglial cells by β -amyloid protein and interferon- γ ," <i>Nature</i> , 374:647-650 (1995).		
— DF 137	Miller et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <i>J. Exp. Med.</i> , 174:791-798 (1991).		
— DF 139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).		
— DR 143	Quon et al., "Formation of β -Amyloid protein deposits in brains of transgenic mice," <i>Nature</i> , 352:239-241 (1991).		
— DL 146	Rogers et al., "Complement activation by β -amyloid in Alzheimer Disease," <i>PNAS</i> , 89:1-5 (1992).		
— DM 147	Rossor et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <i>Annals of New York Academy of Sciences</i> , 695:198-202 (1993).		
— DN 152	Selkoe, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <i>Scientific American</i> , pgs. 68-78 (11/91).		
— DE 153	Selkoe, Dennis J., "In the Beginning....," <i>Nature</i> , 354:432-433 (1991).		
— DP 154	Selkoe, Dennis J., "The Molecular pathology of Alzheimer's Disease," <i>Neuron</i> , 6:487-498 (1991).		

FORM PTO-1449 (Modified)		Attorney Docket No.: 15270-004740US	Application No.: 09/322,289
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Dale B. Schenk	
		Filing Date: May 28, 1999	Group: 1648
<u>DC</u> 155	Selkoe, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <i>Science</i> , 275:630-631 (1997).		
<u>DR</u> 157	Shiosaka, Sadao, "Attempts to make models for Alzheimer's disease," <i>Neuroscience Res.</i> , 13:237-255 (1992).		
<u>DS</u> 162	Solomon, B., "New Approach Towards Fast Induction of Anti β -Amyloid Peptide Immune Response," Department of Molecular Microbiology & Biotechnology, Tel-Aviv University, ramat Aviv, Tel-Aviv, Israel. ^(Publication) DATE UNKNOWN		
<u>DT</u> 165	Tanaka et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).		
<u>DT</u> 166	Trieb et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37, (1994).		
<u>DY</u> 168	Verbeek et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Amer. Journ. Pathology</i> , 144(1):104-116 (1994).		
<u>DW</u> 169	Walker et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <i>J. Neuropath. Exp. Neurology</i> , 53(4):377-383 (1994).		
<u>DX</u> 171	Weiner et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <i>Annu. Rev. Immunol.</i> , 12:809-837 (1994).		
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)			Attorney Docket No.: 15270-004740US		Application No.: 09/322,289	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			Applicant: Dale B. Schenk			
			Filing Date: May 28, 1999		Group: 1648	
Reference Designation			U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA 3	5,955,317	9/21/99	Suzuki et al.			
AB 4	5,955,079	9/21/99	Mond et al.			
AC 6	5,869,093	2/9/99	Weiner et al.			
AD 7	5,869,054	2/9/99	Weiner et al.			
AE 8	5,854,204	12/29/98	Findeis et al.			
AF 10	5,849,298	12/15/98	Weiner et al.			
AG 12	5,786,180	7/28/98	Konig et al.			
AH 14	5,750,349	5/12/98	Suzuki et al.			
AI 15	5,733,547	3/31/98	Weiner et al.			
AJ 16	5,688,651	11/18/97	Solomon			
AK 18	5,645,820	7/8/97	Hafler et al.			
AL 19	5,641,474	6/24/97	Hafler et al.			
AM 20	5,641,473	6/24/97	Hafler et al.			
AN 23	5,585,100	12/17/96	Mond et al.			
AO 24	5,571,500	11/5/96	Hafler et al.			
AP 25	5,571,499	11/5/96	Hafler et al.			
AQ 26	5,434,170	7/18/95	Andrulis et al.			
AR 27	5,387,742	2/7/95	Cordell			
AS 28	5,231,000	7/27/93	Majocha et al.			
AT 31	5,192,753	3/9/93	McGeer et al.			
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
AX 53	WO 99/60024	11/25/99	PCT			
AX 54	WO 99/60021	11/25/99	PCT			
AX 55	WO 99/58564	11/18/99	PCT			
AX	WO 99/27949	6/10/99	PCT Duplicate			
AY 56	WO 99/06066	2/11/99	PCT			
AZ 63	WO 96/39176	12/12/96	PCT			
BA 64	WO 96/25435	8/22/96	PCT			
BB 65	WO 96/18900	6/20/96	PCT			
BC 66	WO 95/31996	11/30/95	PCT			
BD 70	WO 95/04151	2/9/95	PCT			
BE 71	WO 94/03615	2/17/94	PCT			
BF 73	WO 93/21950	11/11/93	PCT			
BG 74	WO 93/16724	9/2/93	PCT			

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <i>Eur. J. Immunol.</i> 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <i>Soc. for Neuroscience Abstracts</i> 18:764 (1992).	<input type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid β -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <i>Nature Medicine</i> , 6(8) 916-919 (2000).	<input type="checkbox"/>
	213	CHEN et al., "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <i>Neuroscience Letters</i> 125:223-226 (1991).	<input type="checkbox"/>
	214	DEMATTOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 10.1073/pnas.151261398 (2001).	<input type="checkbox"/>
	210	Friedland et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994).	<input type="checkbox"/>
	215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A β - α ," <i>Annals of the New York Academy of Science</i> 920:274-84 (2000).	<input type="checkbox"/>
	190	GRAVINA et al., "Amyloid β Protein (A β) in Alzheimer's Disease," <i>J. Biol. Chem.</i> 270(13):7013-7016 (1995).	<input type="checkbox"/>
	193	HARRINGTON et al., "Characterisation of an epitope specific to the neuron-specific isoform of human enolase recognised by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β / A4-protein," <i>Biochimica Biophysica Acta</i> , 1158:120-128 (1993).	<input type="checkbox"/>
	177	HELMUTH, L., "Further Progress on a β -Amyloid Vaccine," <i>Science</i> , 289:375 (2000).	<input type="checkbox"/>
	192	WATSUBO et al., "Visualization of A β 42(43) and A β 40 in Senile Plaques with End-Specific A β Monoclonals: Evidence That an Initially Deposited Species Is A β 42(43)," <i>Neuron</i> , 13:45-53 (1994).	<input type="checkbox"/>
	216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <i>Am. J. of Pathology</i> 138:373-378 (1991).	<input type="checkbox"/>
	183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <i>Biotechnol. Appl. Biochem.</i> , 23:227-230 (1996).	<input type="checkbox"/>
	195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369 2B Specific for the Carboxyl-Terminus of the A β 4 Peptide," <i>Annals of NY Acad. Sci.</i> , 777:344-355 (1996).	<input type="checkbox"/>
	218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for A β 4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <i>The J. of Nuclear Med.</i> , 33:2184-2189 (1992).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PA 3158407 v3

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/322,289
		Filing Date	May 28, 1999
		First Named Inventor	Schenk, Dale B.
		Group Art Unit	1647
		Examiner Name	S. Turner
		Attorney Docket Number	15270J-004740US
Sheet	3	of	3

217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	<input type="checkbox"/>
206	MORI et al., "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).	<input type="checkbox"/>
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).	<input type="checkbox"/>
144	PASO, V.A., Grant application #1-P42-ACL5745-04, (publication date unknown).	<input type="checkbox"/>
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	<input type="checkbox"/>
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	<input type="checkbox"/>
194	SAIDO et al., "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	<input type="checkbox"/>
178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- β Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	<input type="checkbox"/>
182	SOLOMON et al., "Inhibitory effect of monoclonal antibodies on Alzheimer's β -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	<input type="checkbox"/>
184	SOLOMON et al., "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).	<input type="checkbox"/>
185	SOLOMON et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	<input type="checkbox"/>
186	SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown).	<input type="checkbox"/>
179	SOUTHWICK et al., "Assessment of Amyloid β protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <u>J. Neurochemistry</u> , 66:259-265 (1996).	<input type="checkbox"/>
180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	<input type="checkbox"/>
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>Proc. Natl. Acad. Sci. USA</u> , 82:8729-8732 (1985).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3158407 v3

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Dale B. Schenk
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	196	6,150,091		Pandolfo et al.	11-21-2000	
	1	6,057,367		Stamler et al.	05-02-2000	
	207	5,780,587		Potter	07-14-1998	
	197	5,744,368		Goldhaber et al.	04-28-1998	
	211	5,736,142		Sette et al.	04-07-1998	
	175	5,441,870		Seubert, et al.	08-15-1995	
	181	5,270,165		Van Nostrand et al.	12-14-1993	
	32	5,187,153		Cordell et al.	02-16-93	
	198	5,004,697		Pardridge	04-0201991	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ² (if known)				
	187	EP	783 104	A1		07-09-1997		<input type="checkbox"/>
	199	PCT	00/77178	A1		12-21-2000		<input type="checkbox"/>
	188	PCT	00/43049	A1		07-27-2000		<input type="checkbox"/>
	58	PCT	99/27944	A1		06-10-1999		<input type="checkbox"/>
	203	PCT	99/00150	A2		01-07-1999		<input type="checkbox"/>
	202	PCT	97/21728	A1		06-19-1997		<input type="checkbox"/>
	208	PCT	96/28471	A1		09-19-1996		<input type="checkbox"/>
	200	PCT	95/12815	A1		05-11-1995		<input type="checkbox"/>
	201	PCT	94/28412	A1		12-08-1994		<input type="checkbox"/>
	205	PCT	93/04194	A1		03-04-1993		<input type="checkbox"/>
	87	PCT	89/01343	A1		02-23-1989		<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3158407 v3

Please type a plus sign (+) inside this box



PTO/SB/088 (08-09)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Group Art Unit	1547
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. *	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins." <u>Neuron</u> , 19: 939-945 (1997).	<input type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology." <u>Cur. Opin. Genet. Develop.</u> , 3: 102-109 (1993).	<input type="checkbox"/>
	103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995)	<input type="checkbox"/>
	104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).	<input type="checkbox"/>
	109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F β -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).	<input type="checkbox"/>
	111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).	<input type="checkbox"/>
	112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).	<input type="checkbox"/>
	113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	<input type="checkbox"/>
	114	GLENNER et al., "Alzheimer's Disease and Down Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	<input type="checkbox"/>
	117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	<input type="checkbox"/>
	119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	<input type="checkbox"/>
	120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	<input type="checkbox"/>
	122	HSIAO et al., "Correlative Memory Deficits, A β Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	<input type="checkbox"/>
	126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	<input type="checkbox"/>
	130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3154027 v2

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

132	LEMERE et al., "Mucosal Administration of A β Peptide Decreases Cerebral Amyloid Burden in Pd-Ap β Transgenic Mice," <i>Society for Neuroscience Abstracts</i> , vol. 25, part I, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).	<input type="checkbox"/>
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <i>J. Immunol.</i> , 159: 1383-1392 (1997).	<input type="checkbox"/>
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <i>Acta Neurol. Scand.</i> , 84:441-444 (1991).	<input type="checkbox"/>
135	MC GEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <i>J. Micro. Encap.</i> , 14(2): 197-210 (1997).	<input type="checkbox"/>
138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <i>Am. J. Epidemiol.</i> , 145(11): 959-969 (June 1, 1997).	<input type="checkbox"/>
140	PARECSE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <i>Neuron</i> , 17:553-565 (September 1996).	<input type="checkbox"/>
141	PAUL et al., "Transdermal immunization with large proteins by means of ultra-deformable drug carriers," <i>Eur. J. Immunol.</i> , 25: 3521-3524 (1995).	<input type="checkbox"/>
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <i>Chemical Abstracts</i> , 120(8): pg. 652, column 1, abstract 86406I (1994).	<input type="checkbox"/>
145	RASO, "Immunotherapy of Alzheimer's Disease," <i>Immunotherapy Weekly</i> , Abstract (April 2, 1998).	<input type="checkbox"/>
149	SELKOE, D. J., "Imaging Alzheimer's Amyloid," <i>Nat. Biotech.</i> , 18:823-824 (2000).	<input type="checkbox"/>
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <i>J. Neuropathol. Exp. Neurol.</i> , 53(5): 438-447 (1994).	<input type="checkbox"/>
151	SELKOE, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <i>Trends in Neurosciences</i> , 16(10): 403-409 (1993).	<input type="checkbox"/>
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <i>Nature</i> , 359: 325-327 (1992).	<input type="checkbox"/>
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <i>Vet. Quart.</i> , 19(3): 101-105 (1997).	<input type="checkbox"/>
159	SOLOMON et al., "Disaggregation of Alzheimer β -amyloid by site-directed mAb," <i>PNAS</i> , 94:4106-4112 (1997).	<input type="checkbox"/>
160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β -amyloid peptide," <i>PNAS</i> , 93:452-455 (1996).	<input type="checkbox"/>
161	SOLOMON, A., "Pro-B β (Protein Therapeutics)," <i>University of Tennessee Medical Center</i> (publication date unknown).	<input type="checkbox"/>
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium falciparum</i> Malaria," <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997).	<input type="checkbox"/>

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3154027 v2

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	09/322,289
Filing Date	May 28, 1999
First Named Inventor	Schenk, Dale B.
Group Art Unit	1647
Examiner Name	S. Turner
Attorney Docket Number	15270J-004740US

164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <u>PNAS</u> , 94: 13287-13292 (1997).	<input type="checkbox"/>
172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).	<input type="checkbox"/>
173	WOOD et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS</u> , 94: 1550-1555 (1997).	<input type="checkbox"/>
174	Human Immunology & Cancer Program brochure from The University of Tennessee Medical Center Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	<input type="checkbox"/>

Examiner
Signature

/Daniel Kolker/

Date
Considered

12/09/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3154027 v2